ASAlbert Kagina Sinyigaya
@DrSinyigaya · X
Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors https://t.co/Ueo61NKXIx
Apr 14, 2022 · 619 followers
View post →
J Lipid Atheroscler September 2019 PMID 32821708
Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors.
Mentions
4
Peak: 2 in Sep 2021
across 2 sources since Sep 2021
Extended reach
62,760
potential audience
Total likes
1,805
Video views
62,124
Mentions per month
Sep 2021 – Jun 2025Where it's discussed
-
X / Twitter2 posts
-
YouTube2 videos
AI synopsis
What people are saying
The discussions reflect a moderate level of agreement, with some posts highlighting the potential of ezetimibe and PCSK9 inhibitors as valuable additions to statin therapy, using words like 'useful' and 'promising.' Participants express interest through questions and comments about the safety and cost, and some delve into implications for patient care, indicating a balanced but engaged conversation about the article's significance.
AgreementModerate agreement
Most discussions acknowledge the relevance of the article, showing moderate support for its findings and implications.
InterestModerate interest
Participants demonstrate noticeable interest, engaging with the subject matter without extreme enthusiasm.
EngagementModerate engagement
Comments include references to specific pharmacological agents and their clinical relevance, indicating thoughtful engagement.
ImpactModerate impact
The discussions suggest that the article could influence clinical or research perspectives, but without overwhelming excitement.
Abstract in brief
- Statins are effective for reducing cardiovascular risk but may not fully lower LDL cholesterol, leaving some residual risk.
- Ezetimibe, a cholesterol absorption inhibitor, can be added to statins to further reduce LDL levels safely and is helpful for patients with statin side effects.
- PCSK9 inhibitors like alirocumab and evolocumab are powerful LDL-lowering agents that are used alongside statins, although they are costly and can cause injection site reactions.
Top posts
Most liked on X and Bluesky
JAJLA (Journal of Lipid and Atherosclerosis)
@JLA_OFFICE · X
Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors https://t.co/2BJQalhkNI
Sep 5, 2021 · 18 followers
View post →
All mentions
Understanding Statins: Effectiveness, Risks, and Alternatives in Heart Health
Today, we delve into statins, key in cardiovascular prevention. We explore their history, benefits in reducing heart attack and stroke risks, potential side effects, and differences between types. Learn how to prescribe…
Dr Gregoire CAUCHOIS - Cardiologue · Jun 4, 2025
61,730 views
Advances in Lipid-Lowering Therapies: Ezetimibe and PCSK9 Inhibitors
Statins effectively reduce cardiovascular risk but may leave residual LDL cholesterol. Ezetimibe and PCSK9 inhibitors, used with statins, further lower LDL levels, offering options for patients with side effects or…
JLA: Journal of Lipid and Atherosclerosis · Sep 5, 2021
395 views
Albert Kagina Sinyigaya
@DrSinyigaya · X
Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors https://t.co/Ueo61NKXIx
Apr 14, 2022 · 619 followers
View post →
JLA (Journal of Lipid and Atherosclerosis)
@JLA_OFFICE · X
Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors https://t.co/2BJQalhkNI
Sep 5, 2021 · 18 followers
View post →
No mentions from this source yet.